A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
10/2001
10/16/2001	CA2073351C Lysozyme dimers and method of preparing them
10/16/2001	CA2031164C Recombinant herpesvirus of turkeys and live vector vaccines derived thereof
10/16/2001	CA2015470C Fluorinated arachidonic acid derivatives
10/14/2001	CA2344183A1 Glycoprotein having inhibitory activity against helicobacter pylori colonization
10/11/2001	WO2001075072A2 PRODUCTION OF TcR GAMMA DELTA T CELLS
10/11/2001	WO2001074898A2 Charged compounds comprising a nucleic acid binding moiety and uses therefor
10/11/2001	WO2001074896A1 Human polynucleotides, polypeptides, and antibodies
10/11/2001	WO2001074855A2 Compositions and methods for dendritic cell-based immunotherapy
10/11/2001	WO2001074816A1 4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamides as antiviral agents
10/11/2001	WO2001074812A1 Novel benzosultam oxazolidinone antibacterial agents
10/11/2001	WO2001074811A2 Substituted 1,3-thiazole compounds, their production and use
10/11/2001	WO2001074808A1 Novel 1,2,3,4-tetrahydrosioquinoline, their preparation method and their use as fungicides
10/11/2001	WO2001074806A1 Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain
10/11/2001	WO2001074790A2 Novel compounds for enhancing chemotherapy
10/11/2001	WO2001074788A1 2-hydroxy-mutilin carbamate derivatives for antibacterial use
10/11/2001	WO2001074787A2 Crystalline pharmaceutical
10/11/2001	WO2001074772A1 Chemokine receptor antagonists
10/11/2001	WO2001074769A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors
10/11/2001	WO2001074768A2 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
10/11/2001	WO2001074761A1 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds
10/11/2001	WO2001074400A1 Transporters and drug delivery system by using the same
10/11/2001	WO2001074387A1 Use of aliphatic quaternary ammonium as adjuvant in a pharmaceutical composition administered by mucosal delivery
10/11/2001	WO2001074386A2 Cold-adapted equine influenza viruses
10/11/2001	WO2001074382A1 Method of treatment using ligand-immunogen conjugates
10/11/2001	WO2001074372A1 Process for producing antibacterial agent originating in tear grass
10/11/2001	WO2001074370A1 Use of feracryl for the treatment of peptic/duodenal ulcer and/or cholera
10/11/2001	WO2001074341A2 Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant
10/11/2001	WO2001074333A1 D and l etherlipid stereoisomers and liposomes
10/11/2001	WO2001074329A2 Sustained release beadlets containing stavudine
10/11/2001	WO2001074295A2 Phospholipid scramblases and methods of use thereof
10/11/2001	WO2001074128A2 A novel polypeptide, microtubulin 11 and the polynucleotide encoding the polypeptide
10/11/2001	WO2001049319A8 Composition containing bacterial antigens, used for the prophylaxis and the treatment of allergic diseases
10/11/2001	WO2001031003B1 Cloning, expression and characterisation of a gene expressed in tumour cells and involved in the regulation of the immune response
10/11/2001	WO2001028556A3 Compositions for prevention and treatment of cold and influenza-like symptoms and their methods of use
10/11/2001	WO2001027119A3 Substance library containing bicyclic imidazo-5-yl-amines and/or bicyclic imidazo-3-yl-amines
10/11/2001	WO2001025269A3 Human g-protein coupled receptor
10/11/2001	WO2001024763A3 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
10/11/2001	WO2001022994A3 Vaccines against neisseria infection
10/11/2001	WO2001021587A3 Hydroxyfunctional amide 1h-indole derivatives active as spla2 inhibitors
10/11/2001	WO2001018038A3 Isoforms of snare molecules and the uses thereof in modulation of cellular exocytosis
10/11/2001	WO2001012264A3 Topical azathioprine for the treatment of oral autoimmune diseases
10/11/2001	WO2001007625A3 Ehrlichia canis genes and vaccines
10/11/2001	WO2001007470A3 Human nervous system-associated proteins
10/11/2001	WO2000076556A3 High dose radionuclide complexes for bone marrow suppression
10/11/2001	WO2000062736A3 Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion
10/11/2001	WO2000057908A9 Attenuated dengue-1 virus vaccine
10/11/2001	WO2000050633A9 Method for cloning signal transduction intermediates
10/11/2001	WO2000047222A3 Inactivated influenza virus vaccine for nasal or oral administration
10/11/2001	WO2000045823A9 Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
10/11/2001	WO2000042429A3 In vitro model for gastrointestinal inflammation
10/11/2001	WO2000042058A9 Steroid derived antibiotics
10/11/2001	WO2000026240A3 Streptococcal alpha2m-binding protein
10/11/2001	US20010029043 Prokaryotic; transformed with nucleic acid encoding papillomavirus virus major capsid protein that assembles within, such as Salmonella, to form chimeric virus like particles; anticancer, antitumor vaccine
10/11/2001	US20010029041 Isolated, live, attenuated phenotype useful for stimulating protective immune response without producing severe symptoms; respiratory stress
10/11/2001	US20010028880 Administering protein c
10/11/2001	EP1145001A3 (in vitro) model for gastrointestinal inflammation
10/11/2001	EP1144001A3 Inactivated influenza virus vaccine for nasal or oral administration
10/11/2001	DE19964162A1 Verfahren zur Abtötung, Abschwächung und Veränderung von Bakterien, Bakteriophagen, Viren, Virophagen, Prionen und Pilzen mit hohen Drücken Method of killing, mitigation and change of bacteria, bacteriophages, viruses, Virophage, prions and fungi with high pressures
10/11/2001	DE10017480A1 Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren Use of substances that act as MEK inhibitor for the manufacture of a Arneimittels against DNA and RNA viruses
10/11/2001	CA2405299A1 Method of treatment using ligand-immunogen conjugates
10/11/2001	CA2405132A1 2-hydroxy-mutilin carbamate derivatives for antibacterial use
10/11/2001	CA2405126A1 Novel 1,2,3,4-tetrahydrosioquinoline, their preparation method and their use as fungicides
10/11/2001	CA2405043A1 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
10/11/2001	CA2404687A1 Sustained release beadlets containing stavudine
10/11/2001	CA2404665A1 Novel compounds for enhancing chemotherapy
10/11/2001	CA2404628A1 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds
10/11/2001	CA2404384A1 Substituted 1,3-thiazole compounds, their production and use
10/11/2001	CA2404312A1 Chemokine receptor antagonists
10/11/2001	CA2404074A1 Human polynucleotides, polypeptides, and antibodies
10/11/2001	CA2403979A1 Cold-adapted equine influenza viruses
10/11/2001	CA2403964A1 Compositions and methods for dendritic cell-based immunotherapy
10/11/2001	CA2403635A1 Crystalline hydrated lopinavir
10/11/2001	CA2403600A1 Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain
10/11/2001	CA2403537A1 Charged compounds comprising a nucleic acid binding moiety and uses therefor
10/11/2001	CA2402864A1 D and l etherlipid stereoisomers and liposomes
10/11/2001	CA2401137A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors
10/11/2001	CA2401112A1 Use of feracryl for the treatment of peptic/duodenal ulcer and/or cholera
10/11/2001	CA2400057A1 4-oxo-1,4-dihydro¬1,8\|naphthyridine-3-carboxamides as antiviral agents
10/11/2001	CA2399275A1 Novel benzosultam oxazolidinone antibacterial agents
10/10/2001	EP1143001A1 Novel interferon-alpha
10/10/2001	EP1142906A1 A hepatitis B virus (subtype ayw) surface antigen variant
10/10/2001	EP1142902A2 3'-Derivatised oligonucleotide analogues with non-nucleotidic groups, their preparation and use
10/10/2001	EP1142900A1 Siastatin b derivatives having glycosidase inhibitory activities and process for producing the same
10/10/2001	EP1142891A1 Use of 5-Fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis B
10/10/2001	EP1142890A1 Aminopyrazole derivatives
10/10/2001	EP1142889A1 Pyrazole derivatives as anti-inflammatory/analgesic agents
10/10/2001	EP1142872A1 Aromatic heterocycle compounds having hiv integrase inhibiting activities
10/10/2001	EP1142868A1 Amide derivatives
10/10/2001	EP1142574A1 Pharmaceutical formulations comprising amoxycillin and clavulanate
10/10/2001	EP1142573A1 Antibacterial medicinal compositions
10/10/2001	EP1141728A1 Kidney disease detection and treatment
10/10/2001	EP1141717A1 Diagnosis of sepsis using the lps-binding moiety of alkaline phosphatase
10/10/2001	EP1141397A1 Method of sequence identification
10/10/2001	EP1141376A1 Peptidoglycan recognition proteins
10/10/2001	EP1141364A1 Use of the cell's own transport system for transferring nucleic acids across the nuclear membrane
10/10/2001	EP1141360A1 Transgenic rodents and rodent cell lines expressing hiv co-receptors
10/10/2001	EP1141342A2 Use of plus-strand synthesis elements in retroviral vectors
10/10/2001	EP1141334A2 Human glycosylphosphatidylinositol specific phospholipase d variants and uses thereof
10/10/2001	EP1141332A1 Human cyclic nucleotide pdes
10/10/2001	EP1141315A2 Modified hiv env polypeptides

1 ... 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 ... 1798